CoChat
Sign Up
Cited by 3Mesenchymal stem cell researchHematopoietic Stem Cell TransplantationBiomedical Ethics and Regulation

Characterization of dynamical changes in vital signs during allogeneic human umbilical Cord-Derived mesenchymal stem cells infusion

Open access
Wang, Yue, Yu, Haiping, Tang, Hongming, Zhu, Rong, Shi, Yiqi, Xu, Changqin, Li, Yan, Wang, Hua +5 more·2023·Regenerative Therapy
DOI 10.1016/j.reth.2023.07.007PMC PMC10407816
Open this paper in CoChat — free account

Abstract

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), a kind of adult stem cell, were studied for clinical applications in regenerative medicine. To date, the safety evaluations of intravenous infusion of allogeneic hUC-MSCs were focused on fever, infection, malignancy, and death. However, the characteristics of dynamical changes in vital signs during hUC-MSCs infusion are largely unknown. In this study, twenty participants with allogeneic hUC-MSCs transplanted (MSC group) and twenty sex- and age-matched individuals with cardiovascular disease who treated with the equal volume of 0.9% normal saline were recruited (NS group). Heart rate, respiratory rate, oxygen saturation, systolic and diastolic blood pressure, and temperature were monitored at intervals of 15 min during infusion. Adverse events were recorded during infusion and within seven days after infusion. No adverse events were observed during and after infusion in both groups. Compared with the baseline, the mean systolic blood pressure (SBP) levels were significantly decreased at 15 min, 30 min, 45 min and 60 min in the MSC group (all P < 0.05) during infusion. In addition, SBP changed significantly from baseline during hUC-MSCs infusion when compared with that of NS group (P < 0.05). Repeated measures analysis of variance confirmed difference over time on the SBP levels (P < 0.05). Our results showed that the process of allogeneic hUC-MSCs intravenous infusion was safe and the vital signs were stable, whereas a slight decrease in SBP was observed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.reth.2023.07.007

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Riordan et al. is included as a normal part of the scientific literature in articles contributing to meta-analyses and reviews or aiding interpretation of newly reported data.

    “Instead, this retracted article is included as a normal part of the scientific literature in these articles, contributing to metaanalyses and reviews of the current state of stem cell science19,20 or aiding the interpretation of newly reported data.21,22”

    From Why retracted articles can have an influential afterlife—and what to do about it (2026) · cites this paper as [21]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [3]Skyler J.S. Fonseca V.A. Segal K.R. Rosenstock J. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study Diabetes Care 38 2015 1742 1749 26153271 PMC4542273
  2. [4]Lee W.S. Kim H.J. Kim K.I. Kim G.B. Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial Stem Cells Translational Medicine 8 2019 504 511 30835956 PMC6525553
  3. [5]Jiang R. Han Z. Zhuo G. Qu X. Li X. Wang X. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study Front Med 5 2011 94 100 21681681
  4. [6]Park E.H. Lim H.S. Lee S. Roh K. Seo K.W. Kang K.S. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase ia clinical trial Stem Cells Translational Medicine 7 2018 636 642 30112846 PMC6127229
  5. [8]Thompson M. Mei S.H.J. Wolfe D. Champagne J. Fergusson D. Stewart D.J. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis EClinical Medicine 19 2020 100249 PMC6970160 31989101
  6. [9]Riordan N.H. Hincapié M.L. Morales I. Fernández G. Allen N. Leu C. Allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels Stem Cells Translational Medicine 8 2019 1008 1016 31187597 PMC6766688
  7. [10]Zhang J. Lv S. Liu X. Song B. Shi L. Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial Gut Liver 12 2018 73 78 28873511 PMC5753687
  8. [11]Shu L. Niu C. Li R. Huang T. Wang Y. Huang M. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Stem Cell Res Ther 11 2020 361 32811531 PMC7432540
  9. [12]Lu Z. Zhu L. Liu Z. Wu J. Xu Y. Zhang C.J. IV/IT hUC-MSCs infusion in rrms and nmo: a 10-year follow-up study Front Neurol 11 2020 967 33013641 PMC7506071
  10. [13]Wang X. Yin X. Sun W. Bai J. Shen Y. Ao Q. Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up Exp Ther Med 13 2017 2255 2258 28565834 PMC5443306
  11. [14]Yin Y. Hao H. Cheng Y. Gao J. Liu J. Xie Z. The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice Int Immunopharm 60 2018 235 245 29778021
  12. [15]Ortiz L.A. Gambelli F. McBride C. Gaupp D. Baddoo M. Kaminski N. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects Proc Natl Acad Sci U S A 100 2003 8407 8411 12815096 PMC166242
  13. [16]Barbash I.M. Chouraqui P. Baron J. Feinberg M.S. Etzion S. Tessone A. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution Circulation 108 2003 863 868 12900340
  14. [17]Kraitchman D.L. Tatsumi M. Gilson W.D. Ishimori T. Kedziorek D. Walczak P. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction Circulation 112 2005 1451 1461 16129797 PMC1456731
  15. [18]Braid L.R. Wood C.A. Wiese D.M. Ford B.N. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes Cytotherapy 20 2018 232 244 29167063
  16. [20]Chobanian A.V. Bakris G.L. Black H.R. Cushman W.C. Green L.A. Izzo J.L. Jr. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of High blood pressure Hypertension 42 2003 1206 1252 14656957
  17. [21]Lawes C.M. Bennett D.A. Feigin V.L. Rodgers A. Blood pressure and stroke: an overview of published reviews Stroke 35 2004 1024 15053002
  18. [22]Wang J.G. Staessen J.A. Franklin S.S. Fagard R. Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome Hypertension 45 2005 907 913 15837826
  19. [23]de Oliveira L.F. Almeida T.R. Ribeiro Machado M.P. Cuba M.B. Alves A.C. da Silva M.V. Priming mesenchymal stem cells with endothelial growth medium boosts stem cell therapy for systemic arterial hypertension Stem Cell Int 2015 2015 685383 PMC4537741 26300922
  20. [24]Bronckaers A. Hilkens P. Martens W. Gervois P. Ratajczak J. Struys T. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis Pharmacol Ther 143 2014 181 196 24594234
  21. [25]Haug C. Schmid-Kotsas A. Zorn U. Bachem M.G. Schuett S. Gruenert A. Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release Am J Physiol Heart Circ Physiol 279 2000 H2865 H2871 11087242
  22. [26]Grover T.R. Zenge J.P. Parker T.A. Abman S.H. Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus Pediatr Res 52 2002 907 912 12438669
  23. [27]Drucker N.A. Te Winkel J.P. Shelley W.C. Olson K.R. Markel T.A. Inhibiting hydrogen sulfide production in umbilical stem cells reduces their protective effects during experimental necrotizing enterocolitis J Pediatr Surg 54 2019 1168 1173 30879750 PMC6545254
  24. [28]Te Winkel J. John Q.E. Hosfield B.D. Drucker N.A. Das A. Olson K.R. Mesenchymal stem cells promote mesenteric vasodilation through hydrogen sulfide and endothelial nitric oxide Am J Physiol Gastrointest Liver Physiol 317 2019 G441 G446 31343254 PMC6842994
  25. [29]Bagno L. Hatzistergos K.E. Balkan W. Hare J.M. Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges Mol Ther 26 2018 1610 1623 29807782 PMC6037203
  26. [30]Premer C. Blum A. Bellio M.A. Schulman I.H. Hurwitz B.E. Parker M. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells EBioMedicine 2 2015 467 475 26137590 PMC4485912
  27. [31]Lin Y.L. Yet S.F. Hsu Y.T. Wang G.J. Hung S.C. Mesenchymal stem cells ameliorate atherosclerotic lesions via restoring endothelial function Stem CellsTransl Med 4 2015 44 55 PMC4275009 25504897
  28. [32]Wang Y. Qi Z. Yan Z. Ji N. Yang X. Gao D. Mesenchymal stem cell immunomodulation: a novel intervention mechanism in cardiovascular disease Front Cell Dev Biol 9 2022 742088 PMC8790228 35096808
  29. [33]Vanhoutte P.M. Shimokawa H. Tang E.H. Feletou M. Endothelial dysfunction and vascular disease Acta Physiol 196 2009 193 222 19220204
  30. [34]Gift A.G. Stanik J. Karpenick J. Whitmore K. Bolgiano C.S. Oxygen saturation in postoperative patients at low risk for hypoxemia: is oxygen therapy needed? Anesth Analg 80 1995 368 372 7818126
  31. [35]Windrum P. Morris T.C. Drake M.B. Niederwieser D. Ruutu T. Variation in dimethylsulfoxide use in stem cell transplantation: a survey of EBMT centres Bone Marrow Transplant 36 2005 601 603 16044141
  32. [36]Spees J.L. Gregory C.A. Singh H. Tucker H.A. Peister A. Lynch P.J. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy Mol Ther 9 2004 747 756 15120336

Cited by

Sorted by citations

Authors
Wang, Y., Yu, H., Tang, H., Zhu, R., Shi, Y., Xu, C., Li, Y., Wang, H., Chen, Y., Shen, P., Xu, J., Wang, C., & Liu, Z.
Affiliations
  • Tongji University (CN)
  • Shanghai University of Traditional Chinese Medicine (CN)
  • Second Military Medical University (CN)
Corresponding author
  • Xu, Jinfang
  • Wang, Congrong
  • Liu, Zhongmin
ORCID
Venue
Regenerative Therapy
Publisher
Elsevier BV
Published
2023-12
Volume
24
Pages
282-287
ISSN
2352-3204 (ISSN-L)
DOI
10.1016/j.reth.2023.07.007
PMC
PMC10407816
OpenAlex
W4385502671
Cited by
3
References
2
Citations by year
2026: 3
FWCI
0.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Regenerative Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Physiology › Biomedical Ethics and Regulation
Keywords
human umbilical cord mesenchymal stem cells, allogeneic stem cell transplantation, intravenous infusion, vital signs, systolic blood pressure, infusion safety, adverse events, oxygen saturation, heart rate, temperature, regenerative medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review